Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics' [CNBC]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNBC
CEO Adam Steensberg told CNBC that, in the real world, Zealand's drug offers massive potential with very few side effects, and the trial wasn't optimized for maximum weight loss. The company has positioned itself as focused on maintaining weight-loss, rather than the amount of weight loss, as it tries to differentiate itself in the lucrative market. Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for specifically for chronic weight management in adults and adolescents. (Photo by Steve Christo - Corbis/Corbis via Getty Images) Steve Christo - Corbis | Corbis News | Getty Images The chief executive of drugmaker Zealand Pharma sought to calm investors about the latest trial results, which showed patients lost less weight than expected and prompted the stock to fall more than 35%. Speaking to CNBC, CEO Adam Steensberg criticized what he called the “weight loss Olympics,” where markets and companies focus too heavily on the amount of weight lost,
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B [Yahoo! Finance]Yahoo! Finance
- Study Says Ozempic Knockoffs Could Cost $3 [Yahoo! Finance]Yahoo! Finance
- Caliber Launches U.S. Expert Advisory Council to Advance Real-Time Stakeholder Intelligence [Yahoo! Finance]Yahoo! Finance
- China approves Pfizer GLP-1 drug for weight management [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/2/26 - Form 6-K
- 3/2/26 - Form 6-K
- 2/23/26 - Form 6-K
- NVO's page on the SEC website